Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...

In Salt Lake City, biotech founders new and seasoned reflect on ways to ride out the industry’s challenges, such as sending ...

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on ...

As Q1 earnings arrive, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least ...

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...

The FDA is reportedly down to a handful of final candidates to lead CBER, with a potential selection expected in the coming ...

Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier ...

A subsidiary of Indian drugmaker Hetero Group mistakenly packaged two types of antidepressants in packs of sertraline, ...